CSL Limited Sponsored ADR (OTCMKTS:CSLLY) Short Interest Down 32.7% in August

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) was the target of a significant drop in short interest in the month of August. As of August 14th, there was short interest totaling 219,694 shares, a drop of 32.7% from the July 30th total of 326,576 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average trading volume of 154,457 shares, the days-to-cover ratio is presently 1.4 days.

Analyst Ratings Changes

Several analysts recently weighed in on CSLLY shares. Citigroup downgraded CSL from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Canaccord Genuity Group downgraded shares of CSL from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Jefferies Financial Group lowered shares of CSL from a “strong-buy” rating to a “hold” rating in a report on Friday, May 29th. Finally, Zacks Research upgraded shares of CSL from a “strong sell” rating to a “hold” rating in a report on Friday, August 7th. Five research analysts have rated the stock with a Hold rating, According to MarketBeat, the company presently has an average rating of “Hold”.

CSL Trading Down 1.2%

CSL stock opened at $30.56 on Tuesday. CSL has a 1-year low of $16.01 and a 1-year high of $36.28. The business has a fifty day moving average price of $23.45 and a 200-day moving average price of $25.22. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.57 and a quick ratio of 1.15.

CSL Company Profile

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.